Novel Agent for Major Depression Moves to Phase III, Even With Setback

(MedPage Today) — Despite missing the primary endpoint, the novel KV7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.
While the mean reduction…

Source link : https://www.medpagetoday.com/psychiatry/depression/115761

Author :

Publish date : 2025-05-27 15:21:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Novel Agent for Major Depression Moves to Phase III, Even With Setback

Maternal Mental Health Declines Sharply Over 8 Years

CDC Ends COVID Vaccine Recs for Healthy Kids, Pregnant Women

Related Posts

Creatine Supplements Studied in Alzheimer’s Pilot Trial

These Two Stimulants Should Be Contraindicated During Pregnancy, Group Says

RFK Jr.’s MAHA Report Cited Studies That Don’t Appear to Exist

RFK Jr. a ‘Menace’; RN Livestreams Shift; Urologist Congressman vs Young Doctors

Targeted Combo Plus Chemo Improves Survival in BRAF-Mutated CRC

First evidence of ancient birds nesting above the Arctic circle

Creatine Supplements Studied in Alzheimer’s Pilot Trial

These Two Stimulants Should Be Contraindicated During Pregnancy, Group Says

RFK Jr.’s MAHA Report Cited Studies That Don’t Appear to Exist

RFK Jr. a ‘Menace’; RN Livestreams Shift; Urologist Congressman vs Young Doctors

Leprosy was in the Americas long before the arrival of Europeans

Targeted Combo Plus Chemo Improves Survival in BRAF-Mutated CRC

First evidence of ancient birds nesting above the Arctic circle

Here’s What to Know About NB.1.8.1, the COVID Variant Surging in Asia

Categories

Archives